<table border="1" id="t346082649" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5: Significant Drug Interactions with BUTRANS</caption>
<colgroup>
<col width="18*"></col>
<col width="81*"></col>
</colgroup>
<tbody>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Benzodiazepines</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">There have been a number of
reports regarding coma and death associated with the misuse and abuse
of the combination of buprenorphine and benzodiazepines. In many,
but not all of these cases, buprenorphine was misused by self-injection
of crushed buprenorphine tablets. Preclinical studies have shown that
the combination of benzodiazepines and buprenorphine altered the usual
ceiling effect on buprenorphine-induced respiratory depression, making
the respiratory effects of buprenorphine appear similar to those of
full opioid agonists.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Closely monitor patients with
concurrent use of BUTRANS and benzodiazepines. Warn patients that
it is extremely dangerous to self-administer benzodiazepines while
taking BUTRANS, and warn patients to use benzodiazepines concurrently
with BUTRANS only as directed by their physician.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Benzodiazepines
and Other Central Nervous System (CNS) Depressants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Due to additive pharmacologic
effects, the concomitant use of benzodiazepines or other CNS depressants,
including alcohol, can increase the risk of hypotension, respiratory
depression, profound sedation, coma, and death.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Reserve concomitant prescribing
of these drugs for use in patients for whom alternative treatment
options are inadequate. Limit dosages and durations to the minimum
required. Follow patients closely for signs of respiratory depression
and sedation <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#Section_5.4">5.4</linkhtml>)]</content>.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Benzodiazepines and other sedatives/hypnotics,
anxiolytics, tranquilizers, muscle relaxants, general anesthetics,
antipsychotics, other opioids, alcohol.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Inhibitors
of CYP3A4</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of buprenorphine
and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine,
resulting in increased or prolonged opioid effects, particularly when
an inhibitor is added after a stable dose of BUTRANS is achieved.<br/>
<br/>After stopping a CYP3A4 inhibitor, as the effects of
the inhibitor decline, the buprenorphine plasma concentration will
decrease <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)]</content>, potentially resulting in decreased opioid
efficacy or a withdrawal syndrome in patients who had developed physical
dependence to buprenorphine.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">If concomitant use is necessary,
consider dosage reduction of BUTRANS until stable drug effects are
achieved. Monitor patients for respiratory depression and sedation
at frequent intervals.<br/>
<br/>If a CYP3A4 inhibitor
is discontinued, consider increasing the BUTRANS dosage until stable
drug effects are achieved. Monitor for signs of opioid withdrawal.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Macrolide antibiotics (e.g.,
erythromycin), azole-antifungal agents (e.g. ketoconazole), protease
inhibitors (e.g., ritonavir)</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of buprenorphine
 and CYP3A4 inducers can decrease the plasma concentration of buprenorphine <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)]</content>, potentially resulting in decreased efficacy or onset
of a withdrawal syndrome in patients who have developed physical dependence
to buprenorphine.<br/>
<br/>After stopping a CYP3A4 inducer,
as the effects of the inducer decline, the buprenorphine plasma concentration
will increase <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)]</content>, which could increase
or prolong both therapeutic effects and adverse reactions and may
cause serious respiratory depression.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">If concomitant use is necessary,
consider increasing the BUTRANS dosage until stable drug effects are
achieved. Monitor for signs of opioid withdrawal.<br/>
<br/>If a CYP3A4 inducer is discontinued, consider BUTRANS dosage reduction
and monitor for signs of respiratory depression.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Rifampin, carbamazepine, phenytoin</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Serotonergic
Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of opioids
with other drugs that affect the serotonergic neurotransmitter system
has resulted in serotonin syndrome.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">If concomitant use is warranted,
carefully observe the patient, particularly during treatment initiation
and dose adjustment. Discontinue BUTRANS if serotonin syndrome is
suspected.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Selective serotonin reuptake
inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors
(SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor
antagonists, drugs that affect the serotonin neurotransmitter system
(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO)
inhibitors (those intended to treat psychiatric disorders and also
others, such as linezolid and intravenous methylene blue).</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Monoamine
Oxidase Inhibitors (MAOIs)</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">MAOI interactions with opioids
may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory
depression, coma) <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#Section_5.2">5.2</linkhtml>)]</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The use of BUTRANS is not recommended
for patients taking MAOIs or within 14 days of stopping such treatment.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">phenelzine, tranylcypromine,
linezolid</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Mixed Agonist/Antagonist
Opioid Analgesics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">May reduce the analgesic effect
of BUTRANS and/or precipitate withdrawal symptoms.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Avoid concomitant use.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">butorphanol, nalbuphine, pentazocine</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Muscle Relaxants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Buprenorphine may enhance the
neuromuscular blocking action of skeletal muscle relaxants and produce
an increased degree of respiratory depression.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor patients receiving muscle
relaxants and BUTRANS for signs of respiratory depression that may
be greater than otherwise expected and decrease the dosage of BUTRANS
and/or the muscle relaxant as necessary.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Opioids can reduce the efficacy
of diuretics by inducing the release of antidiuretic hormone.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
diminished diuresis and/or effects on blood pressure and increase
the dosage of the diuretic as needed.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Anticholinergic
Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of opioid
analgesics, including buprenorphine, and anticholinergic drugs may
increase the risk of urinary retention and/or severe constipation,
which may lead to paralytic ileus.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
urinary retention or reduced gastric motility when BUTRANS is used
concomitantly with anticholinergic drugs.</td>
</tr>
</tbody>
</table>